ImmunoGen, Inc.
IMU.DE
Deutsche Börse5.17
EUR
- -
- -
ImmunoGen, Inc.
IMU.DE
(Deutsche Börse)
Recent
price
5.17
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ImmunoGen, Inc. (IMU.DE) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for cancer treatment; its core products include ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class FRα-targeted ADC approved for folate receptor-alpha positive, platinum-resistant ovarian cancer, as well as investigational assets such as IMGN-151, a next-generation FRα ADC, and pivekimab sunirine, a CD123-targeted ADC in Phase 2 for blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia. The company employs its proprietary Targeted Antibody Payload technology, featuring maytansinoid payloads like DM1, DM4, and DNA-acting IGN agents linked to tumor-targeting antibodies, to create therapies for solid tumors and hematologic malignancies including ovarian, endometrial, non-small cell lung cancers, and acute myeloid leukemia. Founded in 1981 and headquartered in Waltham, Massachusetts, ImmunoGen previously operated independently with collaborations including Roche (Kadcyla), Amgen, Bayer, Eli Lilly, Novartis, Sanofi, and others; it now functions as a subsidiary of AbbVie Inc. following AbbVie's $10.1 billion acquisition completed in February 2024, which integrates ImmunoGen's ADC pipeline into AbbVie's oncology portfolio to accelerate development across multiple tumor types.